These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33305681)

  • 41. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants.
    Suh J; Moon KC; Jung JH; Lee J; Song WH; Kang YJ; Jeong CW; Kwak C; Kim HH; Ku JH
    Sci Rep; 2019 Oct; 9(1):15268. PubMed ID: 31649294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
    Ferro M; Di Lorenzo G; Vartolomei MD; Bruzzese D; Cantiello F; Lucarelli G; Musi G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; Gabriele A; Del Giudice F; Damiano R; Perri F; Perdona S; Verze P; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Autorino R; Crisan N; Farhan ARA; Battaglia M; Russo GI; Ieluzzi V; Morgia G; De Placido P; Terracciano D; Cimmino A; Scafuri L; Mirone V; De Cobelli O; Shariat S; Sonpavde G; Buonerba C
    World J Urol; 2020 Jan; 38(1):143-150. PubMed ID: 30993426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
    Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe).
    Jahnson S; Gårdmark T; Hosseini A; Jerlström T; Liedberg F; Malmström PU; Rosell J; Sherif A; Ströck V; Häggström C; Holmberg L; Aljabery F
    Scand J Urol; 2019 Aug; 53(4):200-205. PubMed ID: 31144582
    [No Abstract]   [Full Text] [Related]  

  • 47. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe).
    Häggström C; Liedberg F; Hagberg O; Aljabery F; Ströck V; Hosseini A; Gårdmark T; Sherif A; Malmström PU; Garmo H; Jahnson S; Holmberg L
    BMJ Open; 2017 Sep; 7(9):e016606. PubMed ID: 28963292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    Gore JL; Wolff EM; Comstock BA; Follmer KM; Nash MG; Basu A; Chisolm S; MacLean DB; Lee JR; Lotan Y; Porten SP; Steinberg GD; Chang SS; Gilbert SM; Kessler LG; Smith AB;
    BMC Cancer; 2023 Nov; 23(1):1127. PubMed ID: 37980511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
    Zieger K; Jensen KM
    Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
    Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
    Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
    Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
    PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.
    Soria F; Pisano F; Gontero P; Palou J; Joniau S; Serretta V; Larré S; Di Stasi S; van Rhijn B; Witjes JA; Grotenhuis A; Colombo R; Briganti A; Babjuk M; Soukup V; Malmstrom PU; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Dalbagni G; Shariat SF; Xylinas E; Karnes RJ; Sylvester R
    World J Urol; 2018 Nov; 36(11):1775-1781. PubMed ID: 30171454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study.
    Soria F; Milla P; Fiorito C; Pisano F; Sogni F; Di Marco M; Pagliarulo V; Dosio F; Gontero P
    World J Urol; 2016 Feb; 34(2):189-95. PubMed ID: 26026818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
    Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Non-muscle invasive bladder cancer].
    Irani J
    Rev Prat; 2014 Dec; 64(10):1382-5. PubMed ID: 25665317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG; Neulander E; Murphy WM; Wajsman Z
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.